BioCentury
ARTICLE | Product Development

MD Anderson AACR data in heavily pretreated lymphoma patients offer long-awaited lift to Affimed

April 10, 2021 2:37 AM UTC

Affimed has been working on NK cell engagers since before T cell engagers became popular but the latest data — which catapulted Affimed over the $1 billion market cap threshold — suggest the approach is gaining momentum.

AACR data released Friday showed cord blood-derived NK cells precomplexed with Affimed’s lead Innate Cell Engager, AFM13, reduced disease in the four heavily pretreated Hodgkin lymphoma patients, all of whom had previously received Adcetris brentuximab vedotin from Seagen Inc. (NASDAQ:SGEN)...